Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/120190
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPathak, R.en
dc.contributor.authorSanders, P.en
dc.contributor.authorDeo, R.en
dc.date.issued2018en
dc.identifier.citationEuropean Heart Journal, 2018; 39(31):2859-2866en
dc.identifier.issn0195-668Xen
dc.identifier.issn1522-9645en
dc.identifier.urihttp://hdl.handle.net/2440/120190-
dc.description.abstractSudden cardiac death (SCD) accounts for approximately one-third of all deaths among patients with non-ischaemic cardiomyopathy (NICM). Implantable cardioverter-defibrillator (ICD) therapy has been the primary intervention for managing individuals at high risk for SCD. However, individual ICD trials in the NICM population have failed to demonstrate a mortality benefit with prophylactic ICD implantation. Current guidelines recommend ICD implantation in NICM patients with symptomatic heart failure and a left ventricular ≤35% and are based on meta-analyses of multiple trials that span three decades and include the recent Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischaemic Heart Failure on Mortality (DANISH) trial. These pooled analyses report a significant reduction in all-cause mortality with ICD implantation compared with medical therapy alone. In addition, each of these trials has demonstrated consistently a reduction in the risk of SCD compared with medical therapy alone. As a result, a refined approach of risk stratification that selects patients at the highest risk for SCD may lead to a significant improvement in ICD efficacy. In this clinical review, we first discuss the evolution of clinical trials that have evaluated ICDs in the NICM population. We then highlight some key markers of arrhythmia risk that hold promise in personalizing risk stratification for SCD.en
dc.description.statementofresponsibilityRajeev K. Pathak, Prashanthan Sanders and Rajat Deoen
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsPublished on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.en
dc.subjectHumans; Cardiomyopathies; Death, Sudden, Cardiac; Genetic Markers; Risk Assessment; Defibrillators, Implantable; Primary Prevention; Ventricular Remodeling; Arrhythmias, Cardiacen
dc.titlePrimary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathyen
dc.typeJournal articleen
dc.identifier.rmid0030102287en
dc.identifier.doi10.1093/eurheartj/ehy344en
dc.identifier.pubid441150-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS14en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidPathak, R. [0000-0002-7391-6867]en
dc.identifier.orcidSanders, P. [0000-0003-3803-8429]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.